Alcon: Take A Look At Vision Care

person using macbook pro on black table

Image Source: Unsplash

Founded in 1945 and based in Switzerland, Alcon AG (ALC) is a global provider of ophthalmic surgery and vision care products. Previously a subsidiary of Novartis AG (NVS), Alcon became an independent company in April, 2019, recalls Jasper Hellweg, an analyst with Argus Research.

We have a favorable view of the company’s market position and product pipeline, and note that sales growth has outpaced increases in marketing and selling costs, resulting in higher margins. Additionally, Alcon continues to launch new products, including the Clareon Toris intraocular lens in the U.S.

Outside of its own development efforts, the company has also relied on acquisitions to drive growth. On Aug. 22, Alcon announced an agreement to acquire Aerie Pharmaceuticals, a developer of ophthalmic therapies, for $770 million.

Through the acquisition, the company will add Rocklatan and Rhopressa, two medications for glaucoma and ocular hypertension, to its portfolio, as well as a Phase 3 product candidate for dry eye disease and a pipeline of other clinical and preclinical ophthalmic product candidates.

We believe that ALC shares are attractively valued at current prices near $58, near the low end of their 52-week range of $56-$89. The shares have fallen substantially over the past year, but recently reached a support line near their IPO price and the 38.2% Fibonacci retracement level, as measured between the stock’s all-time high and all-time low.

If the stock is able to hold this level, we look for a gradual rebound in the stock to its 61.8% level, near $70 per share. Meanwhile, a drop below the current line of support could indicate further downside to the next support level near $51.

On the fundamentals, ALC has a short trading history. It is trading at 22-times our 2023 EPS estimate. We expect Alcon to benefit over time from its strong product pipeline and recent acquisitions, as well as from a continued recovery in surgical volumes. Our rating remains "buy" with a revised target price of $70 a share.


About the Author

At Argus Research, Jasper Hellweg covers growth pharmaceutical, medical technology, and financial technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a bachelor of science degree in business administration with concentrations in entrepreneurship and marketing.

Prior to joining Argus, Mr. Hellweg worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report, and Argus' bespoke research on IPOs.


More By This Author:

Thornburg: An "Income Builder"
Five Reasons To Buy Alphabet
Goodyear Tire Keeps Rolling On

Disclaimer: © 2022 MoneyShow.com, LLC. All Rights Reserved.

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.